A
Alise S. Reicin
Researcher at Merck & Co.
Publications - 36
Citations - 8360
Alise S. Reicin is an academic researcher from Merck & Co.. The author has contributed to research in topics: Etoricoxib & Rofecoxib. The author has an hindex of 25, co-authored 36 publications receiving 8011 citations. Previous affiliations of Alise S. Reicin include Penn State Milton S. Hershey Medical Center & McGill University Health Centre.
Papers
More filters
Journal ArticleDOI
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier,Loren Laine,Alise S. Reicin,Deborah R. Shapiro,Ruben Burgos-Vargas,Barry R. Davis,Richard O. Day,Marcos Bosi Ferraz,Christopher J. Hawkey,Marc C. Hochberg,Tore K Kvien,Thomas J. Schnitzer +11 more
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Journal ArticleDOI
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials
Colin Baigent,Neeraj Bhala,Jonathan Emberson,A Merhi,S. Abramson,Nadir Arber,John A. Baron,Claire Bombardier,Christopher P. Cannon,Michael E. Farkouh,Garret A. FitzGerald,Paul E. Goss,Heather Halls,Ernest T. Hawk,Christopher J. Hawkey,C H Hennekens,Marc C. Hochberg,Lisa Holland,Patricia M. Kearney,Loren Laine,Angel Lanas,Peter Lance,Andreas Laupacis,Jim C. Oates,Carlo Patrono,Thomas J. Schnitzer,Scott D. Solomon,Peter Tugwell,Kate Wilson,Janet Wittes,O. Adelowo,P. Aisen,Abdulaziz A Al-Quorain,Roy D. Altman,George L. Bakris,H. Baumgartner,C. Bresee,M. Carducci,D. M. Chang,C. T. Chou,D. Clegg,M. Cudkowicz,L. Doody,Y. El Miedany,Claire Falandry,J. Farley,Leslie G. Ford,M. Garcia-Losa,M. Gonzalez-Ortiz,M. Haghighi,M. Hala,T. Iwama,Zrinka Jajić,David J. Kerr,H. S. Kim,C.-H. Köhne,B. K. Koo,Barbara K. Martin,Curtis L. Meinert,N. Muller,G. Myklebust,D. Neustadt,R. Omdal,S. Ozgocmen,A. Papas,Paola Patrignani,F. Pelliccia,V. Roy,I. Schlegelmilch,Asad Umar,O. Wahlstrom,F. Wollheim,S. Yocum,X. Y. Zhang,E. Hall,Patricia McGettigan,R Midgley,R. A. Moore,R. Philipson,Sean P. Curtis,Alise S. Reicin,John H. Bond,Ami R. Moore,M. Essex,J. Fabule,B. Morrison,Leslie Tive,Kelly Davies,F. Yau +88 more
TL;DR: Although NSAIDs increase vascular and gastrointestinal risks, the size of these risks can be predicted, which could help guide clinical decision making.
Journal ArticleDOI
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison
Christopher P. Cannon,Sean P. Curtis,Garret A. FitzGerald,Henry Krum,Amarjot Kaur,James A. Bolognese,Alise S. Reicin,Claire Bombardier,Michael E. Weinblatt,Désirée van der Heijde,Erland Erdmann,Loren Laine +11 more
TL;DR: Rates of thrombotic cardiovascular events in patients with arthritis on etoricoxib are similar to those in patients on diclofenac with long-term use of these drugs.
Journal ArticleDOI
Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
Loren Laine,Laurine G. Connors,Alise S. Reicin,Christopher J. Hawkey,Ruben Burgos Vargas,Thomas J. Schnitzer,Qinfen Yu,Claire Bombardier +7 more
TL;DR: Serious lower GI events occurred at a rate of 0.9% per year in rheumatoid arthritis patients taking the nonselective NSAID naproxen, accounting for nearly 40% of the serious GI events that developed in these patients.
Journal ArticleDOI
Cardiovascular Thrombotic Events in Controlled, Clinical Trials of Rofecoxib
Marvin A. Konstam,Matthew R. Weir,Alise S. Reicin,Deborah R. Shapiro,Rhoda S. Sperling,Eliav Barr,Barry J. Gertz +6 more
TL;DR: A combined analysis of individual patient data was undertaken to determine whether there was an excess of CV thrombotic events in patients treated with rofecoxib compared with those treated with placebo or nonselective NSAIDs.